GLP-1 (Glucagon-like Peptide-1) is a natural incretin hormone that: Stimulates insulin secretion (when glucose is high) Suppresses glucagon release Slows gastric emptying Increases satiety reducing food intake Why GLP-1 Therapy Stands Out Glycemic Control Lowers HbA1c by ~11.5% with minimal hypoglycemia risk Weight Loss 515 kg depending on drug/dose (semaglutide leads the way) Cardiovascular Protection Reduced major CV events (MACE) in trials like LEADER, SUSTAIN, REWIND Renal Protection Slows progression of diabetic kidney disease Convenience Available as daily or weekly injections and even oral semaglutide Key Clinical Trials LEADER (Liraglutide) CV mortality & MACE SUSTAIN-6 (Semaglutide) CV events & strong weight loss REWIND (Dulaglutide) CV protection even in lower-risk populations STEP Trials (Semaglutide) Double-digit weight reduction in obesity The Bigger Picture GLP-1 therapy goes beyond insulin and beyond diabetes
Because it is cheaper to produce, it can be made in a laboratory and added to most vitamins and dietary supplements. Cyanocobalamin has a cyanide donor, a substance that is not intended to be used in the body
For example, the above Catalonian and Canary Island studies returned values of 3.8% and 8.5% for these age groups
Dual Function: It acts as both a delivery system for copper and a signalling molecule for gene expression
Menjaga kesehatan jantung
Asimismo, su accin antioxidante ofrece proteccin adicional frente al dao vascular
